HER2-TARGETED THERAPIES

A retrospective analysis of 1,047 patients with breast cancer who received trastuzumab therapy found that cardiology involvement (including guideline-adherent cardiovascular monitoring and risk factor management) was associated with an average 1.5 mm Hg (95% CI: –2.9 to –0.1; p = .035) lower systolic blood pressure and with a lower BMI in patients with baseline BMI ≥25 kg/m² (mean difference: –0.5 kg/m²; 95% CI: –1.0 to –0.1; p = .027). Cardiology involvement was associated with a higher rate of guideline-adherent cardiac monitoring and improved systolic BP control.